- Overview & Objectives
- Credit Eligibility
- Funding Support
Date
Apr 15, 2025Time
7:00 - 8:30 pm EDTCredits
Non-certified creditsDetails
Virtual (Free)Description
This program covered the key clinical trial findings and their implications from ACC 2025. This program is intended for cardiovascular specialists and primary care physicians.
Learning Objectives
Following participation in this program, participants will be able to:
- Review trials and data presented at ACC 2025
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice
Discussion Topics
- SOUL – Cardiovascular benefits of an oral GLP-1 receptor agonist
- RIVAWAR – Rivaroxaban vs. warfarin for acute LV thrombus post-MI
- STRIDE – Clinical effects of weekly semaglutide in patients with peripheral arterial disease
- TAVR Updates – The role of TAVR in aortic insufficiency and in low-risk aortic stenosis
Faculty
Milan Gupta: MD, FRCPC, FCCS, CPC(HC)
Narendra Singh: MD, FRCPC, FCCS, FACC, FAHA
